Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Sep;41(9):595-8.
doi: 10.3760/cma.j.issn.0529-5807.2012.09.005.

[Correlation between KRAS mutations and clinicopathologic features in colorectal carcinomas]

[Article in Chinese]
Jie Gao  1 , Jing Zhang, Tao Lu, Xiao-yuan Li, Ning Jia, Zhi-yong Liang
Affiliations

[Correlation between KRAS mutations and clinicopathologic features in colorectal carcinomas]

[Article in Chinese]
Jie Gao et al. Zhonghua Bing Li Xue Za Zhi. 2012 Sep.

Abstract

Objective: To investigate mutations of KRAS gene and clinicopathological characteristics of colorectal carcinomas (CRC) in Chinese.

Methods: Tumor cells were collected by microdissection from paraffin-embedded tumor specimens and adjacent normal colon tissues from 167 CRC patients. Genomic DNA was extracted and mutations of KRAS gene (codons 12 and 13) were detected by scorpions amplification refractory mutation system (Scorpions ARMS).

Results: KRAS mutations were identified in 66 patients (39.5%), including G13D (21 cases, 12.6%), G12D (15 cases, 9.0%), G12V (13 cases, 7.8%), G12C (6 cases, 3.6%), G12A (5 cases, 3.0%), G12S (4 cases, 2.4%) and G12R (2 cases, 1.2%). Female patients had a higher KRAS mutation rate than male (50.0%, 29/58 vs.33.9%, 37/109, P < 0.05). However, KRAS mutations did not correlate with the patient age, tumor sites, histological types and grades (P > 0.05). Additionally, 7 of 18 patients with metastatic CRC had KRAS gene mutations. Overall, KRAS gene mutation was identified in 59 patients among 149 primary CRC (39.6%). There was no significant difference in KRAS mutation between primary and metastatic tumors (P > 0.05).

Conclusions: The detection rate of KRAS mutation is higher in female CRC patients than the males. The presence of KRAS mutation does not significantly correlate with the patients' age, tumor site, differentiation grades and histological types. There was no significant difference in KRAS mutation between the primary and metastatic tumors.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

MeSH terms